DOCSLIB.ORG

Federal Register/Vol. 81, No. 195/Friday, October 7, 2016/Rules

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Federal Register/Vol. 81, No. 195/Friday, October 7, 2016/Rules Federal Register / Vol. 81, No. 195 / Friday, October 7, 2016 / Rules and Regulations 69677 Methapyrilene: All drug products Sparteine sulfate: All drug products SUMMARY: The Department of the Navy containing methapyrilene. containing sparteine sulfate. (DoN) is amending its certifications and Methopholine: All drug products Sulfadimethoxine: All drug products exemptions under the International containing methopholine. containing sulfadimethoxine. Regulations for Preventing Collisions at Methoxyflurane: All drug products Sulfathiazole: All drug products Sea, 1972 (72 COLREGS), to reflect that containing methoxyflurane. containing sulfathiazole (except for the Deputy Assistant Judge Advocate Mibefradil dihydrochloride: All drug those formulated for vaginal use). General (DAJAG) (Admiralty and products containing mibefradil Suprofen: All drug products Maritime Law) has determined that USS dihydrochloride. containing suprofen (except ophthalmic SIOUX CITY (LCS 11) is a vessel of the Nitrofurazone: All drug products solutions). Navy which, due to its special containing nitrofurazone (except topical Sweet spirits of nitre: All drug construction and purpose, cannot fully drug products formulated for products containing sweet spirits of comply with certain provisions of the 72 dermatologic application). nitre. COLREGS without interfering with its Nomifensine maleate: All drug Tegaserod maleate: All drug products special function as a naval ship. The products containing nomifensine containing tegaserod maleate. intended effect of this rule is to warn Temafloxacin hydrochloride: All drug maleate. mariners in waters where 72 COLREGS Novobiocin sodium: All drug products products containing temafloxacin apply. containing novobiocin sodium. hydrochloride. Oxyphenisatin: All drug products Terfenadine: All drug products DATES: This rule is effective October 7, containing oxyphenisatin. containing terfenadine. 2016 and is applicable beginning Oxyphenisatin acetate: All drug 3,3′,4′,5-tetrachlorosalicylanilide: All September 23, 2016. products containing oxyphenisatin drug products containing 3,3′,4′,5- FOR FURTHER INFORMATION CONTACT: acetate. tetrachlorosalicylanilide. Commander Theron R. Korsak, JAGC, Pemoline: All drug products Tetracycline: All liquid oral drug U.S. Navy, Admiralty Attorney, containing pemoline. products formulated for pediatric use (Admiralty and Maritime Law), Office of Pergolide mesylate: All drug products containing tetracycline in a the Judge Advocate General, Department containing pergolide mesylate. concentration greater than 25 of the Navy, 1322 Patterson Ave. SE., Phenacetin: All drug products milligrams/milliliter. Suite 3000, Washington Navy Yard, DC containing phenacetin. Ticrynafen: All drug products 20374–5066, telephone number: 202– Phenformin hydrochloride: All drug containing ticrynafen. 685–5040. products containing phenformin Tribromsalan: All drug products SUPPLEMENTARY INFORMATION: Pursuant hydrochloride. containing tribromsalan. to the authority granted in 33 U.S.C. Phenylpropanolamine: All drug Trichloroethane: All aerosol drug 1605, the DoN amends 32 CFR part 706. products containing products intended for inhalation This amendment provides notice that phenylpropanolamine. containing trichloroethane. the DAJAG (Admiralty and Maritime Pipamazine: All drug products Troglitazone: All drug products Law), under authority delegated by the containing pipamazine. containing troglitazone. Polyethylene glycol 3350, sodium Secretary of the Navy, has certified that Trovafloxacin mesylate: All drug USS SIOUX CITY (LCS 11) is a vessel chloride, sodium bicarbonate, products containing trovafloxacin potassium chloride, and bisacodyl: All of the Navy which, due to its special mesylate. construction and purpose, cannot fully drug products containing polyethylene Urethane: All drug products comply with the following specific glycol 3350, sodium chloride, sodium containing urethane. bicarbonate, and potassium chloride for Valdecoxib: All drug products provisions of 72 COLREGS without oral solution, and 10 milligrams or more containing valdecoxib. interfering with its special function as a of bisacodyl delayed-release tablets. Vinyl chloride: All aerosol drug naval ship: Annex I paragraph 2 (a)(i), Potassium arsenite: All drug products products containing vinyl chloride. pertaining to the location of the forward containing potassium arsenite. Zirconium: All aerosol drug products masthead light; Annex I, paragraph 3(a), Potassium chloride: All solid oral containing zirconium. pertaining to the location of the forward dosage form drug products containing Zomepirac sodium: All drug products masthead light, and the horizontal potassium chloride that supply 100 containing zomepirac sodium. distance between the forward and after masthead light. The DAJAG (Admiralty milligrams or more of potassium per Dated: October 3, 2016. and Maritime Law) has also certified dosage unit (except for controlled- Leslie Kux, release dosage forms and those products that the lights involved are located in Associate Commissioner for Policy. formulated for preparation of solution closest possible compliance with the prior to ingestion). [FR Doc. 2016–24333 Filed 10–6–16; 8:45 am] applicable 72 COLREGS requirements. Povidone: All intravenous drug BILLING CODE 4164–01–P Moreover, it has been determined, in products containing povidone. accordance with 32 CFR parts 296 and Propoxyphene: All drug products 701, that publication of this amendment containing propoxyphene. DEPARTMENT OF DEFENSE for public comment prior to adoption is Rapacuronium bromide: All drug impracticable, unnecessary, and products containing rapacuronium Department of the Navy contrary to public interest since it is bromide. based on technical findings that the Reserpine: All oral dosage form drug 32 CFR Part 706 placement of lights on this vessel in a products containing more than 1 manner differently from that prescribed milligram of reserpine. Certifications and Exemptions Under herein will adversely affect the vessel’s Rofecoxib: All drug products the International Regulations for ability to perform its military functions. containing rofecoxib. Preventing Collisions at Sea, 1972 List of Subjects in 32 CFR Part 706 Sibutramine hydrochloride: All drug AGENCY: Department of the Navy, DoD. products containing sibutramine Marine safety, Navigation (water), and ACTION: Final rule. hydrochloride. Vessels. VerDate Sep<11>2014 18:29 Oct 06, 2016 Jkt 241001 PO 00000 Frm 00019 Fmt 4700 Sfmt 4700 E:\FR\FM\07OCR1.SGM 07OCR1 mstockstill on DSK3G9T082PROD with RULES 69678 Federal Register / Vol. 81, No. 195 / Friday, October 7, 2016 / Rules and Regulations For the reasons set forth in the PART 706—CERTIFICATIONS AND ■ a. In Table One, adding, in alpha preamble, the DoN amends part 706 of EXEMPTIONS UNDER THE numerical order, by vessel number, an title 32 of the Code of Federal INTERNATIONAL REGULATIONS FOR entry for USS SIOUX CITY (LCS 11); Regulations as follows: PREVENTING COLLISIONS AT SEA, and 1972 ■ b. In Table Five, adding, in alpha numerical order, by vessel number, an ■ 1. The authority citation for part 706 entry for USS SIOUX CITY (LCS 11). continues to read as follows: § 706.2 Certifications of the Secretary of Authority: 33 U.S.C. 1605. the Navy under Executive Order 11964 and 33 U.S.C. 1605. ■ 2. Section 706.2 is amended by: * * * * * TABLE ONE Distance in meters of forward masthead Vessel Number light below minimum required height. § 2(a)(i) Annex I ******* USS SIOUX CITY .................................................................................................................................... LCS 11 5.98 ******* * * * * * TABLE FIVE Masthead lights Forward After masthead not over all other masthead light not light less than Percentage 1⁄2 ship’s length horizontal Vessel Number lights and in forward quarter aft of forward separation obstructions. of ship. masthead light. attained Annex I, sec. 2(f) Annex I, sec. 3(a) Annex I, sec. 3(a) ******* USS SIOUX CITY ................................... LCS 11 .................................... X X 23 ******* Approved: September 23, 2016. DEPARTMENT OF HOMELAND Orleans event. This deviation allows the A.S. Janin, SECURITY bridge to remain closed-to-navigation Captain, USN, JAGC, Deputy Assistant Judge for ten hours on Saturday and eight Advocate, General (Admiralty and Maritime Coast Guard hours on Sunday. Law). DATES: This deviation is effective from 33 CFR Part 117 Dated: October 3, 2016. 7 a.m. on November 5, 2016 through 3 p.m. on November 6, 2016. C. Mora, [Docket No. USCG–2016–0920] ADDRESSES: The docket for this Commander, Judge Advocate General’s Corps, Drawbridge Operation Regulation; deviation, [USCG–2016–0920] is U.S. Navy, Federal Register Liaison Officer. Inner Harbor Navigation Canal, New available at http://www.regulations.gov. [FR Doc. 2016–24327 Filed 10–6–16; 8:45 am] Orleans, LA FOR FURTHER INFORMATION CONTACT: If BILLING CODE 3810–FF–P AGENCY: Coast Guard, DHS. you have questions on this temporary deviation, call or email Donna Gagliano, ACTION: Notice of deviation from Bridge Administration Branch, Coast drawbridge regulations. Guard, telephone (504) 671–2128, email SUMMARY: The Coast Guard has issued a [email protected]. temporary deviation from the operating SUPPLEMENTARY INFORMATION: Premier schedule that governs the Leon C. Event Management, through the Simon Blvd. (Seabrook) (aka Senator Louisiana Department of Transportation Ted Hickey) bascule bridge across the and Development (LDOTD), requested a Inner Harbor Navigation Canal, mile 4.6, temporary deviation from the operating at New Orleans, Orleans Parish, schedule of the Leon C. Simon Blvd. Louisiana. The deviation is necessary to (Seabrook) (aka Senator Ted Hickey) accommodate The USA Triathlon bascule bridge across the Inner Harbor National Championships, a New Navigation Canal, mile 4.6, at New VerDate Sep<11>2014 18:29 Oct 06, 2016 Jkt 241001 PO 00000 Frm 00020 Fmt 4700 Sfmt 4700 E:\FR\FM\07OCR1.SGM 07OCR1 mstockstill on DSK3G9T082PROD with RULES.
Load more

Recommended publications
  • Biochemistry. in the Article “An Erp60-Like Protein from the Filarial
    9966 Corrections Proc. Natl. Acad. Sci. USA 96 (1999) Biochemistry. In the article “An Erp60-like protein from the Immunology. In the article “Bacteria-induced neo-biosynthe- filarial parasite Dirofilaria immitis has both transglutaminase sis, stabilization, and surface expression of functional class I and protein disulfide isomerase activity” by Ramaswamy molecules in mouse dendritic cells” by Maria Rescigno, Ste- Chandrashekar, Naotoshi Tsuji, Tony Morales, Victor Ozols, fania Citterio, Clotilde The`ry, Michael Rittig, Donata Meda- and Kapil Mehta, which appeared in number 2, January 20, glini, Gianni Pozzi, Sebastian Amigorena, and Paola Ricciardi- 1998, of Proc. Natl. Acad. Sci. USA (95, 531–536), the authors Castagnoli, which appeared in number 9, April 28, 1998, of inadvertently cited the wrong GenBank accession numbers for Proc. Natl. Acad. Sci. USA (95, 5229–5234), the following four database sequences in the figure legend of a dendrogram corrections should be noted. The changes to references 33 and (Fig. 3b) on page 534. The correct accession numbers are 34 are in bold type. shown in the table below. 33. Medaglini, D., Rush, C. M., Sestini, P. & Pozzi, G. C. (1997) Vaccine 15, 1330–1337. Sequence ID Accession no. as published Correct accession no. 34. Rittig, M. G., Kuhn, K., Dechant, C. A., Gaukler, A., Modolell, RATPDI P54001 P04785 M., Ricciardi-Castagnoli, P., Krause, A. & Burmester, G. R. HUMPDI P55059 P07237 (1996) Dev. Comp. Immunol. 20, 393–406. CHICKPDI P16924 P09102 CEPDI Q10576 U95074 Pharmacology. The article “Nonsteroid drug selectives for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associ- Biophysics. In the article “Characterization of lipid bilayer ated with human gastrointestinal toxicity: A full in vitro phases by confocal microscopy and fluorescence correlation analysis” by Timothy D.
    [Show full text]
  • Aspirin and Other Anti-Inflammatory Drugs
    Thorax 2000;55 (Suppl 2):S3–S9 S3 Aspirin and other anti-inflammatory drugs Thorax: first published as 10.1136/thorax.55.suppl_2.S3 on 1 October 2000. Downloaded from Sir John Vane Historical introduction inhibiting COX, thereby reducing prosta- Salicylic acid, the active substance in plants glandin formation, providing a unifying expla- used for thousands of years as medicaments, nation for their therapeutic actions and their was synthesised by Kolbe in Germany in 1874. side eVects. This also firmly established certain MacLagan1 and Stricker2 showed that it was prostaglandins as important mediators of eVective in rheumatic fever. A few years later inflammatory disease (see reviews by Vane and sodium salicylate was also in use as a treatment Botting7 and Vane et al8). COX first cyclises for chronic rheumatoid arthritis and gout as arachidonic acid to form prostaglandin (PG) well as an antiseptic compound. G2 and the peroxidase part of the enzyme then Felix HoVman was a young chemist working reduces PGG2 to PGH2. at Bayer. Legend has it that his father, who was taking salicylic acid to treat his arthritis, Discovery of COX-2 complained to his son about its bitter taste. Over the next 20 years several groups postu- Felix responded by adding an acetyl group to lated the existence of isoforms of COX. Then salicylic acid to make acetylsalicylic acid. Rosen et al,9 studying COX in epithelial cells Heinrich Dreser, the Company’s head of phar- from the trachea, found an increase in activity macology, showed it to be analgesic, anti- of COX during prolonged cell culture.
    [Show full text]
  • Examining Product Risk in Contextmarket Withdrawal of Zomepirac As a Case Study
    Examining Product Risk in Context. Market Withdrawal of Zomepirac as a Case Study The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Ross-Degnan, Dennis. 1993. “Examining Product Risk in Context.” JAMA 270 (16) (October 27): 1937. doi:10.1001/ jama.1993.03510160055029. Published Version doi:10.1001/jama.1993.03510160055029 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:32692587 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA Examining Product Risk in Context Market Withdrawal of Zomepirac as a Case Study Dennis Ross-Degnan, ScD; Stephen B. Soumerai, ScD; Eric E. Fortess, ScD, MPH; Jerry H. Gurwitz, MD Objective.\p=m-\Toexamine changes in the prescribing of analgesics after the mar- as nonsteroidal anti-inflammatory drugs ket entry and subsequent withdrawal of zomepirac sodium, a nonsteroidal anti\x=req-\ (NSAIDs). The drug was first marketed inflammatory drug (NSAID), following repeated reports of zomepirac-related deaths. in the United States by McNeil Phar¬ evaluate this natural we conducted time-series maceutical, Spring House, Pa, in No¬ Design.\p=m-\To quasi experiment, vember under the analyses to compare prescribing in two cohorts of primary care physicians from July 1980, proprietary name Zomax.5 Indications for which it 1980 1983. through September was marketed included relief of moder¬ care to Setting.\p=m-\Studyphysicians provided outpatient pharmaceutical patients ate to severe as well enrolled in the New postoperative pain, Jersey Medicaid program.
    [Show full text]
  • Ibuprofen-Induced Bullous Leukocytoclastic Vasculitis Kimberly A
    continuing medical education Ibuprofen-Induced Bullous Leukocytoclastic Vasculitis Kimberly A. Davidson, King of Prussia, Pennsylvania Franziska Ringpfeil, MD, Philadelphia, Pennsylvania Jason B. Lee, MD, New York, New York GOAL To discuss a case of ibuprofen-induced bullous leukocytoclastic vasculitis (LCV) OBJECTIVES Upon completion of this activity, dermatologists and general practitioners should be able to: 1. List the drugs implicated as causative agents of bullous eruptions. 2. Discuss the diagnosis of suspected drug-related bullous eruptions. 3. Describe the distinguishing characteristics that separate bullous LCV from other bullous eruptions. CME Test on page 308. This article has been peer reviewed and ACCME to provide continuing medical ed- approved by Michael Fisher, MD, Professor ucation for physicians. of Medicine, Albert Einstein College of Albert Einstein College of Medicine Medicine. Review date: March 2001. designates this educational activity for a This activity has been planned and im- maximum of 1.0 hour in category 1 credit plemented in accordance with the Essen- toward the AMA Physician’s Recognition tials and Standards of the Accreditation Award. Each physician should claim only Council for Continuing Medical Education those hours of credit that he/she actually through the joint sponsorship of Albert spent in the educational activity. Einstein College of Medicine and Quadrant This activity has been planned and HealthCom, Inc. The Albert Einstein produced in accordance with ACCME College of Medicine is accredited by the Essentials. A dramatic case of ibuprofen-induced bullous including bullous erythema multiforme, bullous leukocytoclastic vasculitis (LCV) is described in fixed drug eruption, linear IgA bullous dermatosis, a patient with a history of prior sensitization to and bullous pemphigoid.
    [Show full text]
  • Examining Product Risk in Contextmarket Withdrawal Of
    Examining Product Risk in Context. Market Withdrawal of Zomepirac as a Case Study The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Ross-Degnan, Dennis. 1993. “Examining Product Risk in Context.” JAMA 270 (16) (October 27): 1937. doi:10.1001/ jama.1993.03510160055029. Published Version doi:10.1001/jama.1993.03510160055029 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:32692587 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA Examining Product Risk in Context Market Withdrawal of Zomepirac as a Case Study Dennis Ross-Degnan, ScD; Stephen B. Soumerai, ScD; Eric E. Fortess, ScD, MPH; Jerry H. Gurwitz, MD Objective.\p=m-\Toexamine changes in the prescribing of analgesics after the mar- as nonsteroidal anti-inflammatory drugs ket entry and subsequent withdrawal of zomepirac sodium, a nonsteroidal anti\x=req-\ (NSAIDs). The drug was first marketed inflammatory drug (NSAID), following repeated reports of zomepirac-related deaths. in the United States by McNeil Phar¬ evaluate this natural we conducted time-series maceutical, Spring House, Pa, in No¬ Design.\p=m-\To quasi experiment, vember under the analyses to compare prescribing in two cohorts of primary care physicians from July 1980, proprietary name Zomax.5 Indications for which it 1980 1983. through September was marketed included relief of moder¬ care to Setting.\p=m-\Studyphysicians provided outpatient pharmaceutical patients ate to severe as well enrolled in the New postoperative pain, Jersey Medicaid program.
    [Show full text]
  • Doping Control Analysis of 16 Non-Steroidal Anti-Inflammatory Drugs in Equine Plasma Using Liquid Chromatography-Tandem Mass Spectrometry
    American Journal of Analytical Chemistry, 2014, 5, 1184-1199 Published Online December 2014 in SciRes. http://www.scirp.org/journal/ajac http://dx.doi.org/10.4236/ajac.2014.517126 Doping Control Analysis of 16 Non-Steroidal Anti-Inflammatory Drugs in Equine Plasma Using Liquid Chromatography-Tandem Mass Spectrometry Youwen You1*, Cornelius E. Uboh2, Fuyu Guan1, Lawrence R. Soma1 1Department of Clinical Studies, School of Veterinary Medicine, University of Pennsylvania, Kennett Square, PA, USA 2PA Equine Toxicology & Research Center, West Chester University, West Chester, PA, USA Email: *[email protected] Received 28 September 2014; revised 14 November 2014; accepted 29 November 2014 Academic Editor: Schalk de Kock, The Laboratory of The National Horseracing Authority of Southern Africa Turffontein Racecourse, South Africa Copyright © 2014 by authors and Scientific Research Publishing Inc. This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/ Abstract Non-steroidal anti-inflammatory drugs (NSAIDs) are classified as Class 4 agents by the Association of Racing Commissioners International and are banned in racehorses during competition in Pennsylvania (PA). To control the abuse of these agents in racehorses competing in PA, a forensic method for screening and confirmation of the presence of these agents is needed. Equine plasma (0.5 mL) was acidified with 75 µL 1M H3PO4 to increase recovery of the analytes by liquid-liquid extraction using methyl tert-butyl ether (MTBE). Extracted analytes were separated by reversed- phase liquid chromatography using a C8 column under gradient condition. All 16 analytes were detected, quantified and confirmed using a triple quadrupole tandem mass spectrometry with se- lected reaction monitoring (SRM) in both negative and positive electrospray ionization modes.
    [Show full text]
  • Family Practice
    THE JOURNAL OF FAMILY PRACTICE Arianne P.Verhagen, PhD, Is any one analgesic Léonie Damen, PhD, Marjolein Y.Berger, MD, PhD, Jan Passchier, PhD, superior for episodic Vivian Merlijn, PhD, and Bart W. Koes, PhD tension-type headache? Department of General Practice, Erasmus Medical This systematic review suggests good tolerance Centre, Rotterdam, The Netherlands. of any given agent may be the deciding factor From the Department of General Practice (APV, LD, MYB, BWK) and the Practice recommendation drug that is well tolerated by a patient is a Department of Medical T Though all non-narcotic analgesics have reasonable basis for selection. Ibuprofen, Psychology and Psychotherapy equivalent efficacy against tension-type therefore, generally may be advocated. (JP, VM) ® Dowden Health Media headache, ibuprofen’s generally favorable When acetaminophen is preferred. Our side-effect profile makes it a reasonable results suggest NSAIDs might be more firCopyrightst choice. For personal use onlyeffective than acetaminophen for TTH. However, because NSAIDs are allergenic hereas quantitative and qualita- for some people, and they must not be tive analyses of 41 randomized used in association with anticoagulants,2 W controlled trials (RCTs) strongly acetaminophen might be an alternative in suggests that all types of NSAIDs are more these situations. When giving acetamino- effective than placebo (>50% pain relief) phen, the dose of the medication might be against an acute episode of tension-type important due to a possible dose-response headache (TTH), the evidence also shows relationship. that no single nonsteroidal anti-inflamma- tory drug (NSAID) is more effective than Why this review was needed another in this setting.
    [Show full text]
  • Anti-Inflammatory/Analgesic Combination of Alpha
    Patentamt JEuropàischesEuropean Patent Office ® Publication number: 0 1 09 036 Office européen des brevets g "j © EUROPEAN PATENT SPECIFICATION (45) Dateof publication of patent spécification: 02.09.87 (jjj) jnt ci 4- A 61 K 31/415, A 61 K 31/62, (22) Dateoffiling: 08.11.83 (54) Anti-inf lammatory/analgesic combination of alpha-fluoromethylhistidine and a selected non-steroidal anti-inflammatory drug (NSAID). (§) Priority: 15.11.82 US 441581 (73) Proprietor: MERCK & CO. INC. 126, East Lincoln Avenue P.O. Box 2000 Rahway New Jersey 07065 (US) (43) Date of publication of application: 23.05.84 Bulletin 84/21 @ Inventor: Goldenberg, Marvin M. 721 Shackamaxon Drive (45) Publication of the grant of the patent: Westfield New Jersey 07090 (US) 02.09.87 Bulletin 87/36 (74) Representative: Abitz, Walter, Dr.-lng. et al (84) Designated Contracting States: Abitz, Morf, Gritschneder, Freiherr von CH DE FR GB IT LI NL Wittgenstein Postfach 86 01 09 D-8000 Munchen 86 (DE) (§) References cited: EP-A-0 046290 US-A-4325 961 CÛ (£> o o> o Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall CL be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been LU paid. (Art. 99( 1 ) European patent convention). Courier Press, Leamington Spa, England. BACKGROUND OF THE INVENTION This invention relates to novel pharmaceutical combinations comprising a-fluoromethylhistidine (FMH) and a non-steroidal anti-inflammatory/analgesic drug (NSAID) particularly indomethacin, diflunisal and naproxen.
    [Show full text]
  • The Multiple Faces of Nonsteroidal Antiinflammatory Drug Hypersensitivity M
    M. Sánchez-Borges, et al. Original Article The multiple faces of nonsteroidal antiinflammatory drug hypersensitivity M. Sánchez-Borges1,2, A. Capriles-Hulett1,3, F. Caballero-Fonseca1,3 1 Centro Médico-Docente La Trinidad, 2 Clínica El Avila, 3 Centro Médico de Caracas, Caracas, Venezuela Summary. Based on the clinical picture and triggering drugs, allergic and pseudoallergic adverse reactions to nonsteroidal anti-inflammatory drugs (NSAIDs) can be classified in four patterns : respiratory, cutaneous, mixed and systemic. This categorization is useful for the purpose of describing patient populations included in studies about NSAID adverse reactions as well as for the routine management of the patient in the clinical setting. Key words: Non steroidal anti-inflammatory drugs. Urticaria. Angioedema. Asthma. Cysteinil-leukotrienes. Cyclooxygenases. Introduction and pseudoallergic reactions to drugs that inhibit cyclooxygenase enzymes [2]. In this paper we would like Nonsteroidal anti-inflammatory drugs (NSAIDs) are to discuss in detail the clinical features of these reactions recognized among the most frequently used therapeutic in an attempt to give clinicians further insights for the agents all over the world, and average consumption has better management of patients suffering from them. For been estimated as high as 80 tablets per person per year the purpose of this article, four clinical patterns will be [1]. Due to the magnitude of exposure, it is not surprising analyzed: 1) Respiratory 2) Cutaneous 3) Mixed 4) Sys- that NSAIDs are one
    [Show full text]
  • Zomepirac Elisa Kit Instructions Product #109619 & 109616 Forensic Use Only
    Neogen Corporation 944 Nandino Blvd., Lexington KY 40511 USA 800/477-8201 USA/Canada | 859/254-1221 Fax: 859/255-5532 | E-mail: [email protected] | Web: www.neogen.com/Toxicology ZOMEPIRAC ELISA KIT INSTRUCTIONS PRODUCT #109619 & 109616 FORENSIC USE ONLY INTENDED USE: For the determination of trace quantities of Zomepirac and/or other metabolites in human urine, blood, oral fluid. DESCRIPTION Neogen Corporation’s Zomepirac ELISA (Enzyme-Linked ImmunoSorbent Assay) test kit is a qualitative one-step kit designed for use as a screening device for the detection of drugs and/or their metabolites. The kit was designed for screening purposes and is intended for forensic use only. It is recommended that all suspect samples be confirmed by a quantitative method such as gas chromatography/mass spectrometry (GC/MS). ASSAY PRINCIPLES Neogen Corporation’s test kit operates on the basis of competition between the drug or its metabolite in the sample and the drug-enzyme conjugate for a limited number of antibody binding sites. First, the sample or control is added to the microplate. Next, the diluted drug-enzyme conjugate is added and the mixture is incubated at room temperature. During this incubation, the drug in the sample or the drug-enzyme conjugate binds to antibody immobilized in the microplate wells. After incubation, the plate is washed 3 times to remove any unbound sample or drug-enzyme conjugate. The presence of bound drug-enzyme conjugate is recognized by the addition of K-Blue® Substrate (TMB). After a 30 minute substrate incubation, the reaction is halted with the addition of Red Stop Solution.
    [Show full text]
  • Plants As Sources of Anti-Inflammatory Agents
    molecules Review Plants as Sources of Anti-Inflammatory Agents Clara dos Reis Nunes 1 , Mariana Barreto Arantes 1, Silvia Menezes de Faria Pereira 1, Larissa Leandro da Cruz 1, Michel de Souza Passos 2, Luana Pereira de Moraes 1, Ivo José Curcino Vieira 2 and Daniela Barros de Oliveira 1,* 1 Laboratório de Tecnologia de Alimentos, Centro de Ciências e Tecnologias Agropecuárias, Universidade Estadual do Norte Fluminense Darcy Ribeiro, Campos dos Goytacazes, RJ 28013-602, Brazil; [email protected] (C.d.R.N.); [email protected] (M.B.A.); [email protected] (S.M.d.F.P.); [email protected] (L.L.d.C.); [email protected] (L.P.d.M.) 2 Laboratório de Ciências Químicas, Centro de Ciências e Tecnologia, UniversidadeEstadual do Norte Fluminense Darcy Ribeiro, Campos dos Goytacazes, RJ 28013-602, Brazil; [email protected] (M.d.S.P.); [email protected] (I.J.C.V.) * Correspondence: [email protected]; Tel.: +55-22-988395160 Academic Editors: Thea Magrone, Rodrigo Valenzuela and Karel Šmejkal Received: 29 June 2020; Accepted: 5 August 2020; Published: 15 August 2020 Abstract: Plants represent the main source of molecules for the development of new drugs, which intensifies the interest of transnational industries in searching for substances obtained from plant sources, especially since the vast majority of species have not yet been studied chemically or biologically, particularly concerning anti-inflammatory action. Anti-inflammatory drugs can interfere in the pathophysiological process of inflammation, to minimize tissue damage and provide greater comfort to the patient. Therefore, it is important to note that due to the existence of a large number of species available for research, the successful development of new naturally occurring anti-inflammatory drugs depends mainly on a multidisciplinary effort to find new molecules.
    [Show full text]
  • Selecting Nonsteroidal Anti-Inflammatory Drugs: J Am Board Fam Pract: First Published As 10.3122/Jabfm.2.4.257 on 1 October 1989
    Selecting Nonsteroidal Anti-Inflammatory Drugs: J Am Board Fam Pract: first published as 10.3122/jabfm.2.4.257 on 1 October 1989. Downloaded from Pharmacologic And Clinical Considerations Lucinda G. Miller, Pharm.D., andJohn G. Prichard, M.D. Abstract: An increasing number of nonsteroidal anti·infIammatory drugs (NSAIDs) are available to treat a variety of conditions. There exist little comparative data examining efficacy for all NSAIDs for a particular illness. The major factors governing selection of these agents relate to the patient's condition and the drug's characteristics. Once efficacy has been established, selection of an NSAID is then determined by side-effect profile, potential for drug interactions, dosing frequency, and cost. This review presents a listing of commerciaIly available NSAIDs, cost comparisons for average daily doses of NSAIDs, and the conditions and drug characteristics that might influence the choice of an NSAID.(J Am Bd Fam Pract 1989; 2:257·71.) Initially, nonsteroidal anti-inflammatory drugs the issue of potency is a minimal consideration (NSAIDs) were developed to provide aspirin when selecting therapy, as dosage recommenda­ alternatives that would have fewer side effects. tions accommodate this factor. Phenylbutazone was first released in 1949, fol­ NSAIDs differ in potency, duration of action, lowed by oxyphenbutazone, I but their use has side-effect profile, potential for drug interactions, been limited by associated blood dyscrasias. In and cost. There exists considerable variability in 1963, indomethacin was introduced and repre­ clinical response to the same agent by different sented an improvement in the side-effect pro­ patients. Although each NSAID must fulfill cri­ file of NSAIDs.
    [Show full text]